Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2018

01-06-2018 | Case report

Sl-401

Various toxicities: 2 case reports

Published in: Reactions Weekly | Issue 1/2018

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Sun W, et al. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: Report of three cases. Journal of Hematology and Oncology 11: 61, No. 1, 2 May 2018. Available from: URL: http://​doi.​org/​10.​1186/​s13045-018-0604-6 - USA
Metadata
Title
Sl-401
Various toxicities: 2 case reports
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2018
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-46988-y

Other articles of this Issue 1/2018

Reactions Weekly 1/2018 Go to the issue

Case report

Haloperidol

Case report

Azithromycin

Case report

Natalizumab

Case report

Procaine benzylpenicillin

Case report

Fluphenazine

Case report

Ipilimumab